IDH2 and central nervous system cancer: IDH mutation promotes tumorigenesis by affecting cell metabolism and its microenvironment, and IDH-mutant gliomas are associated with lower grade and favorable survival (Berzero et al., 2021; Hartmann et al., 2010).